Northwestern researchers report Phase III MS data for HSCT vs. continuing disease-modifying therapies

Researchers at Northwestern University and colleagues reported data from a Phase III trial in 110 patients with highly active relapsing-remitting multiple sclerosis (MS) showing that conditioning with cyclophosphamide and rabbit anti-thymocyte globulin

Read the full 321 word article

How to gain access

Continue reading with a
two-week free trial.